Objective: To determine whether changing antiretroviral therapy (ART) during pregnancy because of concern about fetal risks led to poorer virological outcomes. Methods: All pregnancies in women with HIV-1 infection enrolled in the national multicenter prospective French Perinatal cohort at 14 week gestation or more were included between January 2005 and December 2015, if the mother was on ART at conception with a plasma viral load,50 copies/mL. The reasons for a change in the ART were analyzed according to treatment guidelines at the time of the pregnancy and defined as for safety concerns in the absence of reported maternal intolerance. Virological and pregnancy outcomes were studied by survival analysis and logistic regression adjusted for a propensity score established for each patient according to baseline characteristics. Results: Of 7079 pregnancies in the overall cohort, 1797 had ART at conception with a viral load,50 copies/mL before 14 week gestation. Of these, 22 changed regimens in the first trimester for intolerance, and 411 of the remaining 1775 (23%) solely for safety concerns. The proportion of change was higher when the initial treatment was not recommended in the national guidelines (OR adjusted: 23.1 [14.0-38.2]), than when it was an alternative option (ORa: 2.2 [1.3-3.7]), as compared to recommended first-line regimens. Treatment changes for safety concerns did not lead to poorer virological control, compared with pregnancies without such changes (19.3% vs. 15.6%, HRa: 1.0 [0.7-1.4]). Conclusions: Changing ART early in pregnancy to regimens considered safer for pregnancy, and neonatal health did not have a destabilizing effect on viral suppression.

American Journal of Medical Genetics Part AVolume 132A, Issue 1 p. 110-110 Research Letter Fetal presentation of PHACES syndrome D. Carles, Corresponding Author D. Carles dominique.carles@chu-bordeaux.fr Service d'Anatomie Pathologique, Groupe Hospitalier Pellegrin, Bordeaux, FranceService d'Anatomie Pathologique, Groupe Hospitalier Pellegrin, 33076 Bordeaux Cedex, France.Search for more papers by this authorF. Pelluard, F. Pelluard Service d'Anatomie Pathologique, Groupe Hospitalier Pellegrin, Bordeaux, FranceSearch for more papers by this authorE.M. Alberti, E.M. Alberti Service d'Anatomie Pathologique, Groupe Hospitalier Pellegrin, Bordeaux, FranceSearch for more papers by this authorB. Maugey-Laulom, B. Maugey-Laulom Service d'Imagerie Médicale, Groupe Hospitalier Pellegrin, Bordeaux, FranceSearch for more papers by this authorT.Y. Lin, T.Y. Lin Service de Gynécologie Obstétrique, Centre Hospitalier d'Angoulême, Saint Michel, FranceSearch for more papers by this authorR. Saura, R. Saura Service de Génétique, Groupe Hospitalier Pellegrin, Bordeaux, FranceSearch for more papers by this authorD. Roux, D. Roux Service de Gynécologie Obstétrique, Groupe Hospitalier Pellegrin, Bordeaux, FranceSearch for more papers by this authorD. Lacombe, D. Lacombe Service de Génétique, Groupe Hospitalier Pellegrin, Bordeaux, FranceSearch for more papers by this author D. Carles, Corresponding Author D. Carles dominique.carles@chu-bordeaux.fr Service d'Anatomie Pathologique, Groupe Hospitalier Pellegrin, Bordeaux, FranceService d'Anatomie Pathologique, Groupe Hospitalier Pellegrin, 33076 Bordeaux Cedex, France.Search for more papers by this authorF. Pelluard, F. Pelluard Service d'Anatomie Pathologique, Groupe Hospitalier Pellegrin, Bordeaux, FranceSearch for more papers by this authorE.M. Alberti, E.M. Alberti Service d'Anatomie Pathologique, Groupe Hospitalier Pellegrin, Bordeaux, FranceSearch for more papers by this authorB. Maugey-Laulom, B. Maugey-Laulom Service d'Imagerie Médicale, Groupe Hospitalier Pellegrin, Bordeaux, FranceSearch for more papers by this authorT.Y. Lin, T.Y. Lin Service de Gynécologie Obstétrique, Centre Hospitalier d'Angoulême, Saint Michel, FranceSearch for more papers by this authorR. Saura, R. Saura Service de Génétique, Groupe Hospitalier Pellegrin, Bordeaux, FranceSearch for more papers by this authorD. Roux, D. Roux Service de Gynécologie Obstétrique, Groupe Hospitalier Pellegrin, Bordeaux, FranceSearch for more papers by this authorD. Lacombe, D. Lacombe Service de Génétique, Groupe Hospitalier Pellegrin, Bordeaux, FranceSearch for more papers by this author First published: 18 November 2004 https://doi.org/10.1002/ajmg.a.30367Citations: 10Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat No abstract is available for this article.Citing Literature Volume132A, Issue11 January 2005Pages 110-110 RelatedInformation

To analyse the management of pregnancy after prenatal diagnosis of sex chromosome aneuploidy (SCA) and the factors influencing genetic counselling and parental decision.

OBJECTIVES:To evaluate the feasibility, accuracy and safety of chorionic villus sampling (CVS). METHODS:Ten thousand seven hundred and forty one singleton pregnancies at risk of chromosome abnormalities (96.3%) and gene disorders (2.8%) were referred from 1990 to 1999 to the fetal medicine unit of a teaching hospital. CVS was performed transabdominally after 11 weeks, using a modified freehand ultrasonographically guided technique by 5 operators. Fetal karyotyping was obtained using a direct method before 1995 and was completed by cell culture after 1996. Failed results, feto-placental discrepancy and fetal loss were assessed. RESULTS:Villi were sampled using extra-amniotic puncture (89.4%) and one sampling-device insertion (92.3%). The mean weight of the specimen was 15.2 +/- 6.0 mg. All attempts at sampling were successful, except eight (0.07%). The number of failed results following direct preparation, cell culture and both methods was 20 (0.19%), 23 (0.21%) and 2 (0.02%), respectively. Light maternal cell contamination occurred in less than 1% of the samplings after microscopic selection of the villi, and never interfered with the assessment of karyotyping. All 3 false-negative results (0.03%) were recorded after direct preparation and 2 were corrected by culture. The rate of chromosomal abnormalities confined to the placenta decreased from 1.08% before 1995 to 0.73% after 1996. True fetal mosaicisms were recorded in 7 cases (0.06%). The rate of fetal loss at <28 weeks was 1.64% in all pregnancies and 1.92% when CVS was performed before 13 weeks. Advanced maternal age was the single factor significantly associated with fetal loss. CONCLUSIONS:CVS was feasible, accurate and safe in our institution, as a result of the increasing experience of the operators and the cytogeneticists.

Satellite symposium of the 10th International Congress of Human Genetics 2001 Vienna, Austria, May 15–19, 2001 within the frame of the European Union project COPERNICUS-2